Lee Pharm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

TodayIR: Zhaoke Ophthalmology Limited (6622) Successfully listed on the Main Board of SEHK DJ EQS-News: Zhaoke Ophthalmology Limited (6622) Successfully listed on the Main Board of SEHK EQS-News / 29/04/2021 / 12:16 UTC+8 Zhaoke Ophthalmology(6622) Successfully Listed on Main Board of SEHK [April 29, 2021, Hong Kong] Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or the "Company"; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, was successfully listed and ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento ... Sorrento Therapeutics, Inc.March 8, 2021 GMT Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharm. China’s National Medical Products Administration (“NMPA”) clears Lee’s Pharm to conduct a Phase III, multicenter, randomized, double blinded, parallel-group clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKA...